133 related articles for article (PubMed ID: 26666748)
21. Effect of CYP2D6 variants on venlafaxine metabolism in vitro.
Zhan YY; Liang BQ; Wang H; Wang ZH; Weng QH; Dai DP; Cai JP; Hu GX
Xenobiotica; 2016; 46(5):424-9. PubMed ID: 26406933
[TBL] [Abstract][Full Text] [Related]
22. Effects of 24 CYP2D6 variants found in Chinese population on the metabolism of clonidine in vitro.
Li XY; Hu XX; Yang F; Yuan LJ; Cai JP; Hu GX
Chem Biol Interact; 2019 Nov; 313():108840. PubMed ID: 31585114
[TBL] [Abstract][Full Text] [Related]
23. Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity.
ter Laak MA; Temmink AH; Koeken A; van 't Veer NE; van Hattum PR; Cobbaert CM
Pediatr Neurol; 2010 Sep; 43(3):159-62. PubMed ID: 20691935
[TBL] [Abstract][Full Text] [Related]
24. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
Shen H; He MM; Liu H; Wrighton SA; Wang L; Guo B; Li C
Drug Metab Dispos; 2007 Aug; 35(8):1292-300. PubMed ID: 17470523
[TBL] [Abstract][Full Text] [Related]
25. Effect of CYP2D6 genetic polymorphism on the metabolism of citalopram in vitro.
Hu XX; Yuan LJ; Fang P; Mao YH; Zhan YY; Li XY; Dai DP; Cai JP; Hu GX
Drug Metab Pharmacokinet; 2016 Apr; 31(2):133-8. PubMed ID: 27016952
[TBL] [Abstract][Full Text] [Related]
26. Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele.
Cui YM; Teng CH; Pan AX; Yuen E; Yeo KP; Zhou Y; Zhao X; Long AJ; Bangs ME; Wise SD
Br J Clin Pharmacol; 2007 Oct; 64(4):445-9. PubMed ID: 17610534
[TBL] [Abstract][Full Text] [Related]
27. Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes.
Kim SH; Byeon JY; Kim YH; Lee CM; Lee YJ; Jang CG; Lee SY
Sci Rep; 2018 Aug; 8(1):12405. PubMed ID: 30120390
[TBL] [Abstract][Full Text] [Related]
28. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome.
Sauer JM; Long AJ; Ring B; Gillespie JS; Sanburn NP; DeSante KA; Petullo D; VandenBranden MR; Jensen CB; Wrighton SA; Smith BP; Read HA; Witcher JW
J Pharmacol Exp Ther; 2004 Feb; 308(2):410-8. PubMed ID: 14610241
[TBL] [Abstract][Full Text] [Related]
29. Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.
Yu G; Li GF; Markowitz JS
J Child Adolesc Psychopharmacol; 2016 May; 26(4):314-26. PubMed ID: 26859445
[TBL] [Abstract][Full Text] [Related]
30. The Pharmacogenetic Impact on the Pharmacokinetics of ADHD Medications.
Brown JT
Methods Mol Biol; 2022; 2547():427-436. PubMed ID: 36068472
[TBL] [Abstract][Full Text] [Related]
31. Comparison of catalytical activity and stereoselectivity between the recombinant human cytochrome P450 2D6.1 and 2D6.10.
Kong LM; Qian MR; Hu HH; Xu SY; Yu LS; Jiang HD; Chen SQ; Zeng S
Pharmazie; 2012 May; 67(5):440-7. PubMed ID: 22764579
[TBL] [Abstract][Full Text] [Related]
32. Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children.
Dinh JC; Pearce RE; Van Haandel L; Gaedigk A; Leeder JS
Drug Metab Dispos; 2016 Jul; 44(7):1070-9. PubMed ID: 27052878
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D6*10/*10 genotype in healthy Japanese men.
Matsui A; Azuma J; Witcher JW; Long AJ; Sauer JM; Smith BP; DeSante KA; Read HA; Takahashi M; Nakano M
J Clin Pharmacol; 2012 Mar; 52(3):388-403. PubMed ID: 21543662
[TBL] [Abstract][Full Text] [Related]
34. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
[TBL] [Abstract][Full Text] [Related]
35. Effects of CYP2C19 Variants on Fluoxetine Metabolism in vitro.
Fang P; He JY; Han AX; Lan T; Dai DP; Cai JP; Hu GX
Pharmacology; 2017; 100(1-2):91-97. PubMed ID: 28494448
[TBL] [Abstract][Full Text] [Related]
36. In vitro assessment of 24 CYP2D6 allelic isoforms on the metabolism of methadone.
Su Y; Zhan YY; Wang BF; Wang SC; Dai DP; Hu GX; Lin H; Lian QQ; Cai JP
Drug Test Anal; 2017 Feb; 9(2):216-220. PubMed ID: 26968424
[TBL] [Abstract][Full Text] [Related]
37. Potential interactions of methylphenidate and atomoxetine with dextromethorphan.
Ciccone PE; Ramabadran K; Jessen LM
J Am Pharm Assoc (2003); 2006; 46(4):472-8. PubMed ID: 16913391
[TBL] [Abstract][Full Text] [Related]
38. Inter-individual variability of in vivo CYP2D6 activity in different genotypes.
Chiba K; Kato M; Ito T; Suwa T; Sugiyama Y
Drug Metab Pharmacokinet; 2012; 27(4):405-13. PubMed ID: 22277677
[TBL] [Abstract][Full Text] [Related]
39. Translating Pharmacogenetics to Clinical Practice: Do Cytochrome P450 2D6 Ultrarapid Metabolizers Need Higher Atomoxetine Doses?
de Leon J
J Am Acad Child Adolesc Psychiatry; 2015 Jul; 54(7):532-4. PubMed ID: 26088654
[No Abstract] [Full Text] [Related]
40. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics.
Belle DJ; Ernest CS; Sauer JM; Smith BP; Thomasson HR; Witcher JW
J Clin Pharmacol; 2002 Nov; 42(11):1219-27. PubMed ID: 12412820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
